CYP
CYNATA THERAPEUTICS LIMITED
$0.0130
▲ +8.33%
Market cap
$3M
Turnover
$5,000
Last price
$0.0130
Day change
+8.33%
Announcements
21
Range, past year
Open 0.230 · Low 0.010 · Now 0.013 · High 0.435
Open CYP in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CYP momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
38/100
Wyckoff phase
Accumulation64d
Trend stage
Emerging
1 Day
+8.3%
1 Week
+18.2%
1 Month
+18.2%
RSI
57
Avg daily range
7.0%
CYNATA THERAPEUTICS LIMITED scores 38 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 64 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Volume 1.5× 60-day avg
- RSI in healthy zone (57)
- Near-term opportunity score 70
Points to watch
- 60d drawdown -23.1%
- High volatility (ATR 7.0%)
- Thin liquidity
- Risk rating: High
- Composite downside risk elevated
CYP announcements
Recent price-sensitive releases.
- 2026-10-08 Prospectus Renounceable Issue | Disclosure Document
- 2026-10-08 Entitlement Offer & Unmarketable Parcel Sale Facility Renounceable Issue | Issued Capital - Other
- 2026-10-08 Termination of At-the-Market Subscription Deed Progress Report
- 2026-10-07 Cynata Receives R&D TI Refund & Repays R&D TI Loan Periodic Reports - Other | Company Administration - Other
- 2026-09-30 R&D Tax Incentive Loan Facility Extension Progress Report | Debt Facility
- 2026-09-24 Notification under Listing Rule 4.3D Periodic Reports - Other | Company Administration - Other
- 2026-08-31 Appendix 4E & Preliminary Final Report Preliminary Final Report
More Health Care stocks
Most traded in the same sector.